Phase 3 Clinical Trials With Primary Completion Dates in June 2024
This is a list of Phase 3 trials with primary completion dates in June 2024 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| AEZS | Aeterna Zentaris Inc. | 2024-06-01 | Phase 3 | NCT04786873 | A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is |
| AGIO | Agios Pharmaceuticals, Inc. | 2024-06-01 | Phase 3 | NCT03853798 | Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007 |
| ANAB | AnaptysBio, Inc. | 2024-06-01 | Phase 3 | NCT05366855 | Long-Term Safety and Efficacy of Imsidolimab (ANB019) in Subjects With Generalized Pustular Psoriasis |
| APLS | Apellis Pharmaceuticals, Inc. | 2024-06-01 | Phase 3 | NCT05067127 | Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis |
| CORT | Corcept Therapeutics Incorporated | 2024-06-01 | Phase 3 | NCT05257408 | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer |
| EIGR | Eiger BioPharmaceuticals, Inc. | 2024-06-01 | Phase 3 | NCT04727424 | Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms |
| GLYC | GlycoMimetics, Inc. | 2024-06-01 | Phase 3 | NCT03616470 | Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia |
| HLBBF | H. Lundbeck A/S | 2024-06-01 | Phase 3 | NCT05064371 | Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan |
| MIST | Milestone Pharmaceuticals Inc. | 2024-06-01 | Phase 3 | NCT05410860 | Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia |
| PALI | Palisade Bio, Inc. | 2024-06-01 | Phase 3 | NCT05470387 | A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection |
| RLMD | Relmada Therapeutics, Inc. | 2024-06-01 | Phase 3 | NCT04855747 | A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) |
| SCYX | SCYNEXIS, Inc. | 2024-06-01 | Phase 3 | NCT05178862 | A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole |
| SVRA | Savara Inc. | 2024-06-01 | Phase 3 | NCT04544293 | Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) |